News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
269,462 Results
Type
Article (14305)
Company Profile (281)
Press Release (254876)
Multimedia
Podcasts (49)
Webinars (7)
Section
Business (79688)
Career Advice (153)
Deals (13259)
Drug Delivery (35)
Drug Development (50577)
Employer Resources (31)
FDA (5737)
Job Trends (5151)
News (144726)
Policy (10052)
Tag
Academia (917)
Accelerated approval (2)
Adcomms (12)
Allergies (52)
Alliances (21715)
ALS (69)
Alzheimer's disease (851)
Antibody-drug conjugate (ADC) (108)
Approvals (5763)
Artificial intelligence (134)
Autoimmune disease (19)
Automation (6)
Bankruptcy (105)
Best Places to Work (4571)
BIOSECURE Act (6)
Biosimilars (44)
Biotechnology (232)
Bladder cancer (59)
Brain cancer (20)
Breast cancer (161)
Cancer (1532)
Cardiovascular disease (121)
Career advice (134)
Career pathing (2)
CAR-T (124)
Cell therapy (349)
Cervical cancer (9)
Clinical research (41257)
Collaboration (561)
Compensation (281)
Complete response letters (13)
COVID-19 (1039)
CRISPR (44)
C-suite (172)
Cystic fibrosis (78)
Data (1623)
Denatured (11)
Depression (32)
Diabetes (144)
Diagnostics (1304)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (86)
Drug pricing (29)
Drug shortages (3)
Duchenne muscular dystrophy (92)
Earnings (30230)
Editorial (19)
Employer branding (4)
Employer resources (29)
Events (48917)
Executive appointments (479)
FDA (6512)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (518)
Gene editing (103)
Generative AI (10)
Gene therapy (266)
GLP-1 (372)
Government (1085)
Grass and pollen (2)
Guidances (70)
Healthcare (6617)
Huntington's disease (23)
IgA nephropathy (26)
Immunology and inflammation (101)
Indications (20)
Infectious disease (1106)
Inflammatory bowel disease (119)
Inflation Reduction Act (8)
Influenza (20)
Intellectual property (68)
Interviews (18)
IPO (7304)
IRA (11)
Job creations (863)
Job search strategy (127)
Kidney cancer (7)
Labor market (8)
Layoffs (215)
Leadership (3)
Legal (1389)
Liver cancer (35)
Lung cancer (207)
Lymphoma (103)
Machine learning (5)
Management (7)
Manufacturing (150)
MASH (63)
Medical device (2603)
Medtech (2604)
Mergers & acquisitions (6296)
Metabolic disorders (409)
Multiple sclerosis (53)
NASH (13)
Neurodegenerative disease (73)
Neuropsychiatric disorders (25)
Neuroscience (1279)
NextGen: Class of 2025 (2018)
Non-profit (853)
Now hiring (22)
Obesity (197)
Opinion (103)
Ovarian cancer (67)
Pain (45)
Pancreatic cancer (60)
Parkinson's disease (124)
Partnered (8)
Patents (138)
Patient recruitment (83)
Peanut (35)
People (25701)
Pharmaceutical (47)
Pharmacy benefit managers (5)
Phase I (14589)
Phase II (19198)
Phase III (12120)
Pipeline (951)
Policy (49)
Postmarket research (852)
Preclinical (6178)
Press Release (32)
Prostate cancer (64)
Psychedelics (35)
Radiopharmaceuticals (215)
Rare diseases (299)
Real estate (1422)
Recruiting (12)
Regulatory (8694)
Reports (17)
Research institute (940)
Resumes & cover letters (17)
Rett syndrome (5)
RNA editing (5)
RSV (10)
Schizophrenia (64)
Series A (100)
Series B (70)
Service/supplier (1)
Sickle cell disease (41)
Special edition (12)
Spinal muscular atrophy (117)
Sponsored (12)
Startups (1978)
State (1)
Stomach cancer (4)
Supply chain (23)
Tariffs (12)
The Weekly (37)
Vaccines (218)
Venture capitalists (32)
Weight loss (110)
Women's health (15)
Worklife (2)
Date
Today (88)
Last 7 days (635)
Last 30 days (1905)
Last 365 days (19373)
2025 (7140)
2024 (20597)
2023 (22448)
2022 (26871)
2021 (27873)
2020 (23426)
2019 (16270)
2018 (11762)
2017 (13793)
2016 (11887)
2015 (14372)
2014 (10412)
2013 (7490)
2012 (7538)
2011 (7616)
2010 (7429)
Location
Africa (148)
Alabama (43)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17380)
Australia (2946)
California (4091)
Canada (1180)
China (379)
Colorado (153)
Connecticut (156)
Delaware (110)
Europe (37464)
Florida (499)
Georgia (124)
Idaho (16)
Illinois (240)
India (10)
Indiana (94)
Iowa (2)
Japan (80)
Kansas (63)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (494)
Massachusetts (3259)
Michigan (74)
Minnesota (153)
Mississippi (1)
Missouri (24)
Montana (14)
Nebraska (4)
Nevada (17)
New Hampshire (14)
New Jersey (1016)
New Mexico (12)
New York (1095)
North Carolina (572)
North Dakota (5)
Northern California (1833)
Ohio (115)
Oklahoma (9)
Oregon (21)
Pennsylvania (772)
Puerto Rico (6)
Rhode Island (19)
South America (208)
South Carolina (5)
Southern California (1565)
Tennessee (25)
Texas (477)
United States (13976)
Utah (56)
Virginia (84)
Washington D.C. (31)
Washington State (374)
Wisconsin (17)
269,462 Results for "tcr2 therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Lion TCR’s Liocyx-M004 Receives FDA Clearance to Launch Global Multicenter Phase 2 Clinical Trial in HBV-Related Hepatocellular Carcinoma
February 12, 2025
·
5 min read
Drug Development
Replay’s cell therapy product company Syena announces first patient dosed in Phase 1/2 study of TCR-NK cell therapy for multiple myeloma
Replay’s cell therapy product company Syena announces first patient dosed in Phase 1/2 study of TCR-NK cell therapy for multiple myeloma
March 11, 2024
·
5 min read
Press Releases
TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 7, 2025
·
11 min read
Drug Development
Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting
Alaunos Therapeutics, Inc. announced that the Company will present early translational data from the first three patients treated in its ongoing TCR-T Library Phase 1/2 trial at the 2023 American Society of Clinical Oncology Annual Meeting taking place June 2-6, 2023, at the McCormick Place Convention Center in Chicago.
May 25, 2023
·
7 min read
Drug Development
TCR2 Therapeutics’ Gavo-Cel Shows Early Promise in Solid Tumors, Ovarian Cancer
TCR2 Therapeutics announced promising Phase I data for gavo-cel in mesothelin-expression that points toward effects in multiple solid tumors, especially ovarian cancer.
September 28, 2022
·
3 min read
·
Mark Terry
Genetown
TCR2 Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 01, 2022
Therapeutics Inc. announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 7,600 shares of TCR2’s common stock to 2 new non-executive employees.
September 1, 2022
·
2 min read
Press Releases
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting
April 28, 2025
·
2 min read
Press Releases
T-knife Therapeutics Announces Five Presentations at American Association for Cancer Research (AACR) Annual Meeting
March 25, 2025
·
3 min read
Pharm Country
Adaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
Adaptimmune Therapeutics plc (NASDAQ: ADAP) today announced completion of an all-stock transaction in which Adaptimmune has combined with TCR² Therapeutics Inc.
June 1, 2023
·
10 min read
Drug Development
Alaunos Therapeutics Highlights Data from TCR-T Library Phase 1/2 Trial at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference
Alaunos Therapeutics, Inc. today announced early clinical data from the first patient in its ongoing TCR-T Library Phase 1/2 trial.
September 21, 2022
·
6 min read
1 of 26,947
Next
